DiaMedica Therapeutics Inc. Accounts Receivable
DiaMedica Therapeutics Inc. (DMAC) had Accounts Receivable of $244.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $244.00K.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $301.00K.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $258.00K.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $260.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $244.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $301.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $258.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $260.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $161.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $253.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $236.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $290.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $391.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $399.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $369.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $310.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $188.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $57.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $82.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $75.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $88.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $168.00K 10-Q · filed 2022-05-04 |
| 2021-12-31 | $130.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | $104.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $16.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $337.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $340.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $335.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $319.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $985.00K 10-Q · filed 2020-05-13 |
| 2019-12-31 | $823.00K 10-K · filed 2021-03-10 |
| 2019-09-30 | $664.00K 10-Q · filed 2019-11-13 |
| 2019-06-30 | $1.11M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $929.00K 10-Q · filed 2019-05-13 |
| 2018-12-31 | $780.00K 10-K · filed 2020-03-23 |
| 2017-12-31 | $80.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |